

Ticker: NEXM CN **2Q25 net cash:** C\$26m **Project:** Selebi-Phikwe / Selkirk
Market cap: C\$166m **Price:** C\$7.75/sh **Country:** Botswana
REC. (unc): BUY **TARGET (unc):** C\$15.70/sh **RISK RATING (unc):** HIGH

Today's metallurgical test results from Selebi UG positively supports the production of separate high-grade copper (27.6% Cu conc grade, 87% recovery) and nickel-cobalt (10.5% Ni conc grade, 0.59% Co, 55.9% Ni recovery) concentrates that should attract interest from a wide audience of smelters in our view. This scenario eliminates the need for an on-site smelter or hydromet plant (preserved as upside for now) significantly lowering capital costs and operational complexity. On a 'blended recovery' basis, results compare well with our estimated 75% for payable production of SCPe 34ktpa CuEq LOM potential from a nominal 20Mt UG inventory at 1.7Mtpa. While nickel recovery reported today at ~56% is slightly below our modelled estimate of 62% based on previous work, we expect this to be optimized through ongoing studies and finer regrinding to enhance nickel liberation, particularly addressing the 24% lost to copper rougher tailings and 17.6% to nickel cleaner tailings. The 'big win' here today is the impressive copper recovery of 87% to the copper concentrate, surpassing our base case estimate of 74%, with only 2.43% copper reporting to the nickel concentrate (vs 19% in our model). **Bottom line** – the project continues to be de-risked towards a 1H26 PEA, with metallurgy now supporting production of high-grade copper and nickel-cobalt concentrates without an on-site smelter. Making no changes to our model today, **we maintain our BUY rating and our price target of C\$15.70/sh** based on 0.4x C\$509m NPV7% for our nominal 20Mt UG inventory and 1.7Mtpa mine plan at SCP LT prices, plus 'same again' growth by the drill bit. Putting the stock at 0.2xNAV vs copper peers averaging 0.9xNAV. Upside comes from metal prices, asset de-risking (1H26 PEA), resource growth and / or new discoveries.

Metallurgical test work supports high-grade copper concentrate separate from nickel-cobalt

Today, NexMetals Mining reported metallurgical testing at its Selebi Mines in Botswana, highlighted by **87.0% copper recovery** (27.6% Cu concentrate), **55.9% nickel recovery**, and **64.7% cobalt recovery** (10.5% Ni, 0.59% Co concentrate) using a conventional flowsheet with a 75-micron primary grind and 35-micron regrind, conducted by Blue Coast Research in Parksville, Canada. This supports production of separate copper and nickel-cobalt concentrates without an on-site smelter or hydrometallurgical plant. Ongoing mineralogical studies and finer regrind tests aim to improve nickel recovery, while variability testing on Selebi Main and North deposits should support flowsheet optimization and future economic studies.

Why we like NexMetals

1. Existing 107Mt @ 1.1% CuEq in mining-friendly Botswana on infrastructure
2. Geological upside: SCPe >50Mt potential LT through resource extension drilling
3. The UG Selebi Mine (27.7Mt @ 3.0% CuEq MRE) is ~2% payable-recoverable CuEq (55-45 Cu-Ni split), rivaling peers trading >500m-US\$1bn.

Catalysts

- 2H25: Selebi & Selkirk MRE update
- 1H26: PEA
- 1H27: SCPe build start
- 2028: SCPe first production

Research

Brandon Gaspar (Toronto) m +1 437 533 3142 bgaspar@scp-rf.com

Omeet Singh (Toronto) m +1 647 527 7509 osingh@scp-rf.com

Moatasm Almaouie (Toronto) m +1 780 299 5151 malmaouie@scp-rf.com

Ticker: NEXM CN	Price / mkt cap: C\$7.75/sh, C\$166m	P/NAV today: 0.20x	Country: Botswana
Author: B Gaspar	Rec / PT: BUY, C\$15.7/sh	1xNAV7%: C\$39.18/sh	Asset: Selebi-Phikwe / Selkirk


Commodity price	CY23A	CY24A	CY25E	CY26E	CY27E	Resource/Inventory @ SCP LT p:	Mt	CuEq %	NiEq %	%M&I
Cu price (US\$/t)	8,523	9,264	9,604	9,584	9,506	Selkirk 43-101 OP M&I	44 Mt	1.1%	0.5%	0%
Cu price (US\$/t, payable)	6,802	7,393	7,664	7,648	7,586	Selebi-Phikwe M&I (incl. historic)	63 Mt	2.3%	1.0%	11%
Share data (m)	Basic	FD	FF FD			Total M&I	107 Mt	1.3%	0.6%	8%
Shares (m)	21.4	29.6	55.7			SCP Inventory	20 Mt	3.5%	1.6%	
SOTP project valuation*	C\$m		o/ship	NAVx	C\$/sh	Funding: Uses			Funding: Sources	
Selebi-Phikwe @ build start (CY27)	509		100%	1.00x	17.21	Pre-FID expl'n / G&A (C\$m):	53		Net Cash+pre prod'n ITM op (C\$m):	74
Nominal exploration upside	509		100%	1.00x	17.21	Build capex (C\$m):	556		SCPe funding to FID (C\$m):	50
Selkirk nominal @ 1.5% in-situ	66		100%	1.00x	2.24	Fin. cost + WC over DFS (C\$m):	69		Build equity (C\$m):	313
2Q25 net cash	26		100%	1.00x	0.88	Asset purchase agreement (C\$m):	76		65% geared debt (C\$m):	361
Cash from ITM options/warrants	48		100%	1.00x	1.63	Total uses (C\$m)	754		Total sources (C\$m)	798
1XNAV C\$	1,159				39.18	Buffer/ drill budget:	44			

*Build start, ex fin. cost + G&A, dil. for optns not build P/NAV today: 0.20x

1xNPV project (C\$m, ungeared)* sensitized to Cu px and discount rate						Ratio analysis	CY23A	CY24A	CY25E	CY26E	CY27E
Asset NPV (C\$m)	8,000	8,500	9,500	9,800	10,000	Shares out (m)	149.3	168.9	26.8	55.7	55.7
10.0% discount	167	222	332	365	386	EPS (C\$/sh)	-	-	-	-	-
7.0% discount	308	375	509	549	576	CFPS before w/c (C\$/sh)	-	-	-	-	-
5.0% discount	428	506	660	706	737	EV (C\$m)	1,155.8	1,322.1	139.8	105.6	417.1
Ungeared project IRR:	15%	17%	20%	21%	21%	FCF yield (%)	-	-	-	-	-
Asset NPV (C\$/sh)	8,000	8,500	9,500	9,800	10,000	Income statement	CY23A	CY24A	CY25E	CY26E	CY27E
10.0% discount	5.66	7.52	11.22	12.33	13.07	Revenue (C\$m)	-	-	-	-	-
7.0% discount	10.42	12.69	17.21	18.57	19.47	COGS (C\$m)	-	-	-	-	-
5.0% discount	14.48	17.09	22.31	23.88	24.92	Gross profit (C\$m)	-	-	-	-	-

*Project level NPV, excl finance costs and central SGA, discounted to build start

Group valuation over time	Sep-25	Sep-26	Sep-27	Sep-28	Mar-29		CY23A	CY24A	CY25E	CY26E	CY27E
Project NPV	460	492	669	1,006	1,183	Exploration (C\$m)	19.2	29.7	24.5	8.5	8.0
Nominal exploration upside	509	509	509	509	509	Finance costs (C\$m)	2.6	3.1	6.4	-	14.4
Selkirk nominal @ 1.5% in-si	66	66	66	66	66	Tax (C\$m)	(0.5)	-	-	-	-
Central G&A and finance cos	(227)	(213)	(203)	(171)	(152)	Other (C\$m)	2.5	1.7	2.6	2.4	1.8
Net cash prior quarter	36	23	174	(149)	(312)	Net income (C\$m)	(32.4)	(42.4)	(44.5)	(22.9)	(36.3)
Cash from ITM options/warre	48.3	48.3	48.3	48.3	48.3	Cash flow statement	CY23A	CY24A	CY25E	CY26E	CY27E
Total NAV (C\$m)	893	926	1,263	1,310	1,342	EBITDA (C\$m)	(29.2)	(37.4)	(35.4)	(20.5)	(20.0)
FF FD share count (m)	30	35	64	64	64	Add share based (C\$m)	1.3	0.1	(0.0)	(0.0)	(0.0)
1xNAV7%/sh FF FD (C\$/sh)	30.20	26.50	19.80	20.53	21.05	Net change wkg cap (C\$m)	0.2	0.2	(1.1)	-	-
Exit value: 1xNAV/sh company @ 2029 first production (C\$, geared)^						Cash flow ops (C\$m)	(30.9)	(37.6)	(33.6)	(20.4)	(33.8)
1xNAV (C\$m)	8,000	8,500	9,500	9,800	10,000	PP&E - build + sust. (C\$m)	(4.7)	(1.0)	(0.1)	-	(277.8)
10.0% discount	647	769	1,013	1,087	1,135	PP&E - expl'n (C\$m)	(0.5)	-	-	-	-
7.0% discount	906	1,052	1,342	1,429	1,487	Cash flow inv. (C\$m)	(2.5)	(1.0)	(0.1)	(34.7)	(277.8)
5.0% discount	1,124	1,289	1,617	1,716	1,782	Share issue (C\$m)	37.1	27.1	95.6	312.8	-
1xNAV (C\$/sh)	8,000	8,500	9,500	9,800	10,000	Debt draw (repay) (C\$m)	12.0	-	-	-	361.1
10.0% discount	10.14	12.06	15.89	17.04	17.80	Cash flow fin. (C\$m)	46.9	25.3	95.6	312.8	361.1
7.0% discount	14.21	16.49	21.05	22.41	23.32	Net change in cash (C\$m)	14.1	(13.1)	62.0	257.6	49.6
5.0% discount	17.63	20.21	25.36	26.90	27.93	Balance sheet	CY23A	CY24A	CY25E	CY26E	CY27E
Production (Y1 from 1Q29)	Y1	Y2	Y3	Y4	Y5	Cash (C\$m)	19.2	6.1	68.1	325.7	375.3
Production (kt CuEq)^	28.7	35.2	35.2	35.2	35.2	Acc rec. + invet. (C\$m)	1.6	1.5	1.2	1.2	1.2
AISC Co-prod. (US\$/lb CuEq)	2.19	2.09	2.09	2.09	2.09	PP&E & expl'n (C\$m)	17.1	17.3	15.2	12.6	287.9
						Total assets (C\$m)	38.0	25.0	84.5	339.6	664.4



Source: SCP estimates

DISCLOSURES & DISCLAIMERS

This research report (as defined under CRO Rule 3600, Part B) is issued and approved for distribution in Canada by SCP Resource Finance LP ("SCP"), an investment dealer who is a member of The Canadian Investment Regulatory Organization ("CRO") and the Canadian Investor Protection Fund ("CIPF"). This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

DISSEMINATION OF RESEARCH: SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact unsubscribe@scp-rf.com and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

RESEARCH ANALYST CERTIFICATION: Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

UK RESIDENTS: SCP Partners UK Limited ("SCP UK") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. SCP UK and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by SCP UK's clients as part of their advisory services to them or is short term market commentary. Neither SCP UK nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS: This research report was prepared by SCP Resource Finance LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.

ANALYST CERTIFICATION / REGULATION AC: The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

SCP RESOURCE FINANCE EXPLANATION OF RECOMMENDATIONS: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

UNDER REVIEW: The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED (N/R): The stock is not currently rated

Research Disclosure		Response
1	SCP collectively beneficially owns 1% or more of any class of the issuer's equity securities ¹	NO
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	NO
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO
6	SCP is making a market in an equity or equity related security of the issuer	NO
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	YES
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO

SCP Resource Finance Equity Research Ratings:

Summary of Recommendations as of September 2025	
BUY:	53
HOLD:	0
SELL:	0
UNDER REVIEW:	1
TENDER:	0
NOT RATED:	0
TOTAL	54

¹ As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month